Sirolimus Drug-Eluting Balloon Presented as a Potential Alternative to Stents for Larger Arteries

MedAlliance, a Switzerland-based medical technology company that developed the SELUTION Sirolimus Drug-Eluting Balloon (DEB), reported new clinical data at the Transcatheter Cardiovascular Therapeutics (TCT) 2025 Conference in San Francisco. The company was acquired by Cordis (USA) in October 2023 in a transaction valued at USD 1.135 billion (source: company announcement, 2023).

Clinical Findings Presented at TCT 2025

At TCT 2025, investigators presented results from the SELUTION DeNovo clinical trial, which enrolled more than 3,300 patients. According to the data shared at the conference, the sirolimus-eluting balloon achieved outcomes comparable to drug-eluting stents. The trial investigators reported that 80% of patients were treated without the implantation of a permanent stent (source: TCT 2025 presentation).

The SELUTION DEB is designed to deliver sirolimus to the arterial wall during angioplasty while avoiding a permanent implant. The company states that this approach aims to restore blood flow while maintaining vessel structure (source: MedAlliance product documentation).

Founder’s Comments on the Company’s Direction

Reflecting on the development of the technology, Amit Bohora, Co-Founder of MedAlliance, said:

“What began as an idea to rethink stent-based intervention has evolved into a global movement toward stentless treatment. The SELUTION sirolimus-eluting balloon is changing how clinicians approach coronary artery disease—treating patients with less invasive, more natural vessel restoration strategies.”

Under Bohora’s leadership, as per the company, the organisation advanced its R&D, strengthened clinical and regulatory programs, and successfully entered major global markets such as Switzerland, Singapore, and the United States.

Commenting on the acquisition, he added:

“The acquisition by Cordis was not merely a transaction, it was a validation of our mission to bring safer, more effective cardiovascular therapies to patients everywhere. Cordis’s global infrastructure amplifies MedAlliance’s reach, ensuring innovations like SELUTION become accessible to physicians and patients across every continent, including India’s rapidly growing healthcare market.”

He further stated:

“India, with its vast and diverse population, stands at the frontier of this transformation. Technologies like SELUTION can change countless lives by offering treatments that merge world-class science with local accessibility. This journey has reaffirmed my belief that visionary entrepreneurship, guided by purpose, can redefine what’s possible in medicine. This path breaking innovation will change the medical treatment globally saving countless lives.”

Note: Statements attributed to company executives reflect their views and should not be interpreted as independent clinical or regulatory conclusions.